Welcome to our dedicated page for Pliant Therapeutics news (Ticker: PLRX), a resource for investors and traders seeking the latest updates and insights on Pliant Therapeutics stock.
Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company pioneering novel therapies for fibrotic diseases through integrin biology and TGF-β pathway modulation. This page serves as the definitive source for official updates on their research pipeline, clinical trial progress, and regulatory developments.
Investors and researchers will find timely announcements about bexotegrast (PLN-74809), the company’s dual αvβ6/αvβ1 integrin inhibitor currently in Phase 2b trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The resource also covers updates across PLRX’s broader pipeline targeting liver fibrosis, oncology, and neuromuscular conditions.
Key content includes press releases on clinical milestones, peer-reviewed publication highlights, and strategic collaborations. All materials are sourced directly from company disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to PLRX’s latest advancements in small molecule therapeutics. Check regularly for updates on trial enrollment completions, data readouts, and FDA communications related to their antifibrotic programs.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology firm, announced participation in the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 3:45 p.m. ET. Bernard Coulie, M.D., Ph.D., President and CEO, and Éric Lefebvre, M.D., Chief Medical Officer, will engage in a fireside chat accessible via their Investor Relations page. Pliant's lead product, bexotegrast, is focused on treating idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) and has received Fast Track and Orphan Drug Designations. They are also advancing programs for nonalcoholic steatohepatitis (NASH) and solid tumors, with ongoing Phase 2a trials.
Pliant Therapeutics (PLRX) announced it will present three scientific posters at the 2023 American Thoracic Society (ATS) International Conference from May 19-24, 2023, in Washington, DC. Highlights include data from the Phase 2a trial of bexotegrast (PLN-74809), a dual-selective integrin inhibitor being developed for idiopathic pulmonary fibrosis (IPF). Two of the presentations have been selected for featured oral presentations. The company emphasizes the drug's mechanism of action and its ongoing clinical development, which has received FDA Fast Track and Orphan Drug Designations.
FAQ
What is the current stock price of Pliant Therapeutics (PLRX)?
What is the market cap of Pliant Therapeutics (PLRX)?
